Kubo, M., Onishi, H., Kuroki, S., Okido, M., Shimada, K., Yokohata, K., . . . Katano, M. (2012). Short-term and low-dose prednisolone administration reduces aromatase inhibitor–induced arthralgia in patients with breast cancer. Anticancer Research, 32, 2331–2336.
To determine whether short-term and low-dose prednisolone reduces aromatase inhibitor (AI)–induced arthralgias in patients with breast cancer
Prednisolone 5 mg was administered to women once daily in the morning for one week.
Patients were undergoing active antitumor treatment.
The study was a prospective intervention clinical trial.
Joint symptoms improved in 67% of patients immediately after prednisolone, 63% continued to report relief at one month, and 52% at two months. Thirty percent of patients reported an improvement in daily life at one week and one month and 26% at two months.
Results suggest that a low dose of 5 mg of prednisolone given for one week at the initiation of AI therapy can relieve arthralgias in some patients.
While this study suggests that AI-related pain can be reduced in patients with breast cancer using prednisolone, randomized controlled trials are needed that reflect longer follow-up and adverse event monitoring. Insufficient evidence exists to recommend practice implementation.
Krüger, W.H., Bohlius, J., Cornely, O.A., Einsele, H., Hebart, H., Massenkeil, G., . . . Wolf, H.H. (2005). Antimicrobial prophylaxis in allogeneic bone marrow transplantation. Guidelines of the infectious diseases working party (AGIHO) of the German Society of Haematology and Oncology. Annals of Oncology, 16, 1381–1390.
To provide a guideline for the use of antimicrobial prophylaxis for patients in an allogeneic bone marrow transplantation setting.
This was classified as a guideline of evidence-based medicine criteria. The author used a table to rate available evidence-based articles about antimicrobial prophylaxis in allogeneic bone marrow transplant recipients.
Evidence was rated using this table.
Category, Grade Definition
Strength of Recommendation
A Good evidence to support a recommendation for use (strongly recommended)
B Moderate evidence to support a recommendation for use (generally recommended)
C Poor evidence to support a recommendation (optional)
D Moderate evidence to support a recommendation against use (generally not recommended)
E Good evidence to support a recommendation against use (never recommended)
Quality of Evidence
I Evidence from at least one well-executed randomized, controlled trial
II Evidence from at least one well-designed clinical trial without randomization; cohort or
case-controlled analytic studies (preferable from more than one center); multiple time-series
studies; or dramatic results from uncontrolled experiments
III Evidence from opinions of respected authorities based on clinical experience, descriptive
studies, or reports of expert committees.
Bacterial
Al: Fluoroquinolones should be used for antibacterial prophylaxis.
BII: Pneumococcus prophylaxis should be used for any patient with active chronic graft-versus-host disease and for the remainder of the patient's life following splenectomy.
BIII: Patients already receiving Pneumocystis carinii pneumonia (PCP)-prophylaxis with trimethoprim/sulfamethoxazole (TMP-SMZ) should have additional prophylaxis based on the epidemiology for the area and patterns of resistance.
DI: Anti-infectious prophylaxis with intravenous immunoglobulins should be used.
Cytomegalovirus
Preventing Exposure
AIII: All patients being considered for allogeneic stem cell transplant should have anti-cytomegalovirus (CMV) IgG-antibody testing. This is recommended to establish the risk for reactivation (de novo infection).
BIII: CMV-negative transplant candidates and patients should not share drinking cups or eating utensils that have been used by others. If a patient who is CMV-negative is in a monogamous relationship, his/her partner is advised to be CMV-serotested. If his/her partner is positive or the patient is not in a monogamous relationship, condom use during sexual contact is recommended.
Al: Transplant recipients who are CMV-seronegative should receive blood products from donors who have also tested negative. When blood banks lack CMV-negative donors, only leukocyte-depleted red cells and thrombocytes should be issued to this group.
DI: CMV prophylaxis should use preparations of human immunoglobulin for CMV-negative matched related donors.
Preventing Disease and Reactivation
BIII: For a CMV-positive recipient, most transplant physicians recommend a CMV-positive donor.
Al: Any patient at risk for CMV disease should be screened for pp65 antigenemia or nucleic acid using real-time polymerase chain reaction (PCR) at least weekly after transplant from days 10 to 100.
Al: Patients should begin pre-emptive therapy following one positive pp65 or two consecutive PCR results. Pre-emptive therapy is advised for two weeks, followed by another two weeks of maintenance therapy.
AI: In a pre-emptive setting, if the patient has resistance to ganciclovir, switching to foscarnet is recommended.
AI: The recommendation for herpes simplex virus (HSV) reactivation in IgG-positive patients is acyclovir. Acyclovir therapy should begin between the start of conditioning therapy and day 1 after the transplant and should continue until day 30 after stem cell transplantation.
Al: The recommendation of drugs for prophylaxis or therapy of CMV are ganciclovir and foscarnet. (Cidofovir has a BII recommendation.)
EI: High-dose acyclovir and valacyclovir should be used to prevent CMV.
El: Human immunoglobulins should be used for prophylaxis or therapy of CMV.
Herpes Simplex Virus
Preventing Exposure
AIII: Serum tests for anti-HSV serostatus are mandatory.
Preventing Reactivation
AI: Acyclovir should be used for standard reactivation prophylaxis, beginning between the start of conditioning therapy and day 1 posttransplant and continuing to day 30 following stem cell transplant.
CI: Evidence is lacking for the use of acyclovir prophylaxis increased to 100 days or more.
BIII: If repeated reactivation is present after 30 days of prophylaxis, continued therapy is recommended.
EIII: Acyclovir is not recommended for continued HSV prophylaxis at times when gancyclovir or foscarnet is used for CMV therapy or prophylaxis because gancyclovir and foscarnet are effective against HSV in vitro.
CIII: The effectiveness of valacyclovir and famciclovir in preventing HSV reactivation lacks the support of trials, but they are presumed effective.
Varicella-Zoster Virus
AIII: All patients being considered for stem cell transplant should avoid contact with those suspected of active varicella-zoster virus (VZV) infection or reactivation.
BIII: Those living with or in close contact with a transplant patient should be vaccinated before transplant.
AIII: To prevent nosocomial spread, transplant patients with overt VZV disease are to be isolated until all lesions are crusted.
CIII: Long-term acyclovir prophylaxis is not effective for prevention.
Epstein-Barr Virus
AIII: Seronegative transplant candidates and patients with Epstein-Barr virus (EBV) should not share drinking cups or eating utensils that have been used by others. If a patient negative for EBV is in a monogamous relationship, his/her partner is advised to be EBV-serotested. If his/her partner is positive or the patient is not in a monogamous relationship, condom use during sexual contact is recommended.
Community Respiratory Virus
AIII: Exposure prophylaxis is critical in avoiding respiratory syncytial virus, influenza, parainfluenza, and adenovirus.
BII: Those living with or working on units with transplant patients should be vaccinated for influenza.
BIII: Patients should receive a two-week course of amantadine or rimantadine for chemoprophylaxis if vaccination occurred during an influenza outbreak.
Yeasts
CIII: Foods at risk for allowing fungi to colonize in the gastrointestinal (GI) tract should be restricted.
AIII: Hand washing and disinfecting by personnel should be performed to prevent GI-colonizing fungi from reaching patients at risk.
Al: It is recommended to take fluconazole 400 mg/day IV or orally to prevent yeast infections in allogeneic stem cell recipients while they are neutropenic.
BI: One study found itraconazole superior to fluconazole but noted that GI side effects can limit oral use.
EII: Itraconazole is not recommended for yeast prophylaxis because of interactions with metabolism of busulfan.
EI: Itraconazole is not recommended for yeast prophylaxis because of interactions with metabolism of cyclophosphamide.
Molds
AII: Stem cell transplant candidates and patients must avoid construction, renovation, or other areas with dust exposure.
AII: Use of air conditioning with high-efficiency particulate absorption filtration or laminar air flow in transplant units reduces mold spore presence in the air and mortality related to fungal invasion.
BIII: Transplant patients should wear appropriate fitting masks when traveling through or to areas off the transplant unit.
BII: No drug demonstrates effectiveness for the primary prophylaxis of aspergillosis following bone marrow transplant.
DII: Itraconazole capsules are limited based on low bioavailability.
AI: For patients with acute leukemia, itraconazole solution reduced the incidence of invasive aspergillosis if plasma levels were greater than 500 ng/mL.
AIII: Secondary prophylaxis with a drug having systemic effectiveness was recommended despite a lack of trial evidence.
Pneumocystis jiroveci (formerly Pneumocystis carinii)
BIII: Stem cell recipients are not to have contact with patients with known PCP.
AII: TMP-SMZ prophylaxis should be used for all allogeneic transplant patients beginning at engraftment until the completion of immunosuppressive therapy or when chronic graft-versus-host disease is resolved.
AII: Dapsone or aerosolized pentacarinate should be used when TMP-SMZ is contraindicated or when the patient does not tolerate it. Higher breakthrough rates are noted with these alternate drugs.
Toxoplasmosis
AIII: Allograft recipient candidates should be tested for Toxoplasma gondii antibodies to identify risk for reactivation. Education should include ways to avoid exposure.
CIII: Toxoplasma prophylaxis at the time of acute graft-versus-host disease or secondary prophylaxis following history of toxoplasmosis should be performed.
Food
BIII: Foods with a risk of fungi, bacteria, or other contamination should be eliminated during and following stem cell transplant, and safer alternatives should be used (e.g., pasteurized cheese instead of unpasteurized cheese).
Vaccination After Stem Cell Transplant
AIII: Immunity against specific pathogens should be analyzed one year after allogeneic transplant with reimmunization with inactivated vaccine or toxoids.
The article also states that stem cell transplant recipients are not to receive live-attenuated virus vaccination during the two years after transplant. No rating was provided for this “strictly contraindicated” recommendation.
Specific recommendations with strong evidence, AI and EI, should be included in nursing practice guidelines with recommendations for and against practice, respectively. Other recommendations should not be included until higher evidence from trials can be demonstrated or included in the “Evidence Not Established” category.
Kroz, M., Fink, M., Reif, M., Grobbecker, S., Zerm, R., Quetz, M., . . . Gutenbrunner, C. (2013). Multimodal therapy concept and aerobic training in breast cancer patients with chronic cancer-related fatigue. Integrative Cancer Therapies, 12, 301–311.
To investigate the feasibility and effects of a multimodal intervention for fatigue compared to home-based aerobic exercise
Individuals selected which intervention they wanted—home exercise or the multimodal intervention. The multimodal intervention included psychoeducation, including mindfulness-based techniques, sleep education regarding sleep hygiene, restriction and stimulus control, eurythmy therapy involving mind-body exercises, and medicine-oriented painting therapy. Those in the exercise group were asked to carry out 30-minute sessions three to five times weekly. Those in the multimodal group had 225 minutes of activity once weekly over 10 weeks, led by specialists in that therapy. Baseline and follow-up study measures were obtained within three weeks prior to starting the study and within three weeks after completion.
Those in the multimodal group showed a significant reduction in physical fatigue (p = .0342, mean change = -2.1). Those in the multimodal group had a significant improvement in global sleep quality (p = .041, mean change = -2.0).
A multicomponent intervention was seen to be feasible and had a positive impact on rating of physical fatigue and global sleep quality.
A holistic multicomponent approach to manage patient fatigue and sleep disruption may have greater benefit than interventions that only incorporate exercise. Further research is needed to determine what type and intervention components are most effective.
Kroiss, R., Fentiman, I.S., Helmond, F.A., Rymer, J., Foidart, J.M., Bundred, N., … Kubista, E. (2005). The effect of tibolone in postmenopausal women receiving tamoxifen after surgery for breast cancer: A randomised, double-blind, placebo-controlled trial. BJOG, 112, 228–233.
The study assessed the effects of tibolone versus placebo in postmenopausal women receiving tamoxifen, measuring effects on hot flashes, endometrium, and serum lipid and lipoproteins.
Women were randomized to receive 20 mg/day tamoxifen plus 2.5 mg/day tibolone or placebo.
Seventy (70) post-menopausal women less than or equal to 75 years of age (mean age: 58. I years) with Stage IIB or less started on tamoxifen postoperatively. Sixty-seven (67) patients completed the study. I
This was an outpatient, multicenter trial.
The trial was a double-blind, randomized, placebo-controlled, multicenter, pilot study.
The trial's primary end point was frequency and severity of hot flashes at three months. Daily hot flash diaries were used to assess frequency and severity of hot flashes. The Landgren scale assessed intensity of hot flashes and sweats. Patients completed a questionnaire to assess interference of hot flashes and sweats with everyday life. Endometrial biopsies were taken at 6 and 12 months. Monthly diaries assessed the incidence of bleeding or spotting throughout the study. Serum lipid profiles were assessed.
Daily diaries showed no change in the daily number of hot flashes with either tibolone or placebo (p = 0.219) after three months. There was a significant reduction in the severity of hot flashes with tibolone verses placebo (-0.4 versus 0.2, p = 0.031). The Landgren scale showed a mean change in the number of hot flashes of –0.6 with tibolone and +1.1 with placebo after 12 months (p = 0.022). Endometrial biopsies were normal and vaginal bleeding similar in both groups. Significant decrease in triglycerides ( 23% versus 1.4%) and HDL (12% versus 19%) with tibolone versus placebo after 12 months were noted.
The study was limited by its small sample size with less than 100 participants.
The effect of tibolone on recurrence of breast cancer is unknown.
Krohn, M., Listing, M., Tjahjono, G., Reisshauer, A., Peters, E., Klapp, B.F., & Rauchfuss, M. (2011). Depression, mood, stress, and Th1/Th2 immune balance in primary breast cancer patients undergoing classical massage therapy. Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer, 19(9), 1303–1311.
To investigate the short- and long-term effects of classical massage therapy on cytokine responses and the Th1/Th2 ratio, depression, mood, and perceived stress in patients with primary breast cancer; to evaluate the relevance of classical massage therapy in the context of oncologic care
Authors randomized 34 women into two groups. The massage group received a 30-minute classical massage twice per week for five weeks. The control group received standard medical care only. Time points in the study were before intervention, at the end of the five-week intervention period, and at six weeks after the intervention. At these time points, participants completed several measurement instruments, and investigators took blood samples to determine cytokine concentrations and the Th1/Th2 ratio.
Unspecified
Randomized controlled trial
Massage therapy is an efficient treatment for reducing depression in breast cancer patients. Insignificant results concerning immunologic parameters, stress, and mood indicate that further research is needed to determine psychological and immunologic changes associated with massage therapy.
Massage therapy may be an effective intervention to offer to patients who struggle with depression. Additional studies should evaluate the effectivenss of this intervention as well as its effect on immunologic parameters, stress, and mood.
Kroenke, K., Theobald, D., Wu, J., Norton, K., Morrison, G., Carpenter, J., & Tu, W. (2010). Effect of telecare management on pain and depression in patients with cancer: A randomized trial. JAMA: The Journal of the American Medical Association, 304(2), 163–171.
To determine whether centralized telephone-based care management cued by automated symptom monitoring can improve depression and pain in patients with cancer
In this study, called the Indiana Cancer Pain and Depression Trial, centralized telecare management was conducted by a nurse-physician specialist team that worked in concert with automated home-based symptom monitoring. The means of monitoring was interactive voice recording or Internet. A nurse care manager assessed symptom response and medication adherence, provided pain- and depression-specific education, and made treatment adjustments according to evidence-based guidelines. Intervention patients received scheduled calls (at baseline, at 1 week, and at 4 and 12 weeks) and received calls when automated monitoring indicated problems in symptom management. Control group received usual care. Data were collected at baseline and at months 1, 3, 6, and 12.
Randomized controlled trial
This study showed that centralized telecare management with automated symptom monitoring may be a feasible approach for geographically dispersed urban and rural oncology practices. This approach may be effective in improving the pain and depression of cancer patients.
Lack of control of the type of cancer treatment and of the time lapse since treatment might have affected study findings.
Cost will be involved in training the care manager and in the hiring of trained personnel. The cost-effectiveness of the collaborative care model needs to be further examined. Findings suggest that telecare management used with automatic systems cued by patient problems can be an effective approach.
Kroenke, K., Theobald, D., Wu, J., Norton, K., Morrison, G., Carpenter, J., & Tu, W. (2010). Effect of telecare management on pain and depression in patients with cancer: A randomized trial. JAMA, 304, 163–171.
To determine whether centralized telephone-based care management and automated symptom monitoring can reduce depression and pain in patients with cancer
Participants in the intervention group received centralized telecare management, conducted by a nurse-physician specialist team, and automated home-based symptom monitoring by means of interactive voice recording or Internet. The control group received usual care. Data were collected at baseline and at months 1, 3, 6, and 12.
Random controlled trial with double blinding, with stratified randomization by symptom type (pain only, depression only, or both pain and depression)
The intervention may be effective at reducing pain and depression. The intervention proved to be a feasible care approach for geographically dispersed urban and rural oncology practices.
Lack of control over type of cancer treatment and over the time lapse since treatment might have affected study findings.
Cost will be involved in training the care manager and in hiring trained personnel. The cost-effectiveness of the collaborative care model needs to be further examined. Studies show mixed results regarding effect of by-telephone patient management; further work in this area is warranted. Use of technology may be a viable approach to ongoing patient support.
Krischer, M.M., Xu, P., Meade, C.D., & Jacobsen, P.B. (2007). Self-administered stress management training in patients undergoing radiotherapy. Journal of Clinical Oncology, 25, 4657–4662.
The intervention was a self-administered stress management training (SSMT) program for patients treated with radiation therapy. The usual care only (UCO) intervention included the usual psychosocial care typically provided at the institution where patients were receiving treatment. Participants in the SSMT program met individually with a nurse for approximately five minutes to receive instructional materials and explanations. The instructional materials consisted of a 15-minute prerecorded videotape, a 12-page booklet, and a 35-minute prerecorded audiotape titled “Active Relaxation,” which taught paced breathing, active relaxation, and positive thinking with guided imagery instructions. Data were collected at baseline and weeks 1, 2, and 3.
Multiple centers in South Florida
A randomized controlled trial design was used.
SSMT is effective only in those patients receiving radiotherapy with initially higher levels of psychological distress at baseline.
Special training needs include the creation of the SSMT tool (instructional materials, video tables, and audiotapes).
Intervention requires screening for psychological distress.
Kris, M.G., Hesketh, P.J., Somerfield, M.R., Feyer, P., Clark-Snow, R., … Grunberg, S.M. (2006). American Society of Clinical Oncology guideline for antiemetics in oncology: Update 2006. Journal of Clinical Oncology, 24(18), 2932–2947.
To update the 1999 American Society of Clinical Oncology (ASCO) guideline for antiemetics in oncology
The update committee reviewed studies identified through a literature search.
Databases searched were MEDLINE, the National Library of Medicine, and the Cochrane Collaboration Library (1998-Feb. 2006).
Studies were included if they were phase II and III randomized, controlled trials.
The search identified the following studies.
Additional materials provided to the committee were
Kress, H.G., Von der Laage, D., Hoerauf, K.H., Nolte, T., Heiskanen, T., Petersen, R., . . . Jensen, N.H. (2008). A randomized, open, parallel group, multicenter trial to investigate analgesic efficacy and safety of a new transdermal fentanyl patch compared to standard opioid treatment in cancer pain. Journal of Pain and Symptom Management, 36(3), 268–279.
To compare, in clinical practice, the effect and safety of a new matrix fentanyl patch (Fentanyl Improved Transdermal [FIT]) patch) to oral and other transdermal opioid treatment
Patients were randomly assigned to either FIT patch or standard opioid treatment via oral or transdermal route. Morphine was the only rescue medication allowed. Patients could receive radiotherapy and chemotherapy as well as nonpharmacologic and pharmacologic pain management therapies. Patients randomized to FIT therapy switched from existing regimens to FIT therapy by means of standard conversion ratios. Patients had an initial screening visit and four additional visits. Each evening each patient assessed his or her pain and recorded the pain rating in a diary. Adverse events were monitored in follow-up visits through the 30-day trial period and for one week longer. Patients assessed adverse events on a four-point scale and recorded the rating.
Randomized open-label parallel-group design
Results showed no differences, in terms of pain management or adverse effects, between the new transdermal patch and standard transdermal or oral opioid treatment. Findings suggest that the new type of patch is safe and, in terms of efficacy, similar to standard treatments.
Transdermal fentanyl, delivered by means of conventional patch or FIT patch, is an effective means of controlling cancer pain.